Could The UK Be Losing Its Pharma Luster? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Could The UK Be Losing Its Pharma Luster?
Despite initiatives to encourage multinational pharma companies to conduct R&D in the UK, the country may be losing its edge; is Pfizer's decision to exit a key site earlier this year the beginning of a mass exodus?


Pharmaceutical Technology Europe
Volume 23, Issue 5

Has the UK been complacent?

The irony for the UK is that there are a number of longstanding initiatives in place to help strengthen its position in both traditional pharma and biotech R&D. Despite opposing views over pharmaceutical pricing, government and industry representatives often have joint discussions on issues of common concern.

Indeed, in November 1999, the UK government, together with representatives of the domestic pharma industry, set up the Pharmaceutical Industry Competitiveness Task Force (PICTF) to identify steps that could be taken to make the UK more attractive for R&D investment (4). The PICTF team met in April 2000 and published its final recommendations in March 2001. Industry representatives were of the opinion that despite the UK's historically strong performance, traditional factors that had contributed to success in the past, such as established academic excellence in life sciences, could not be relied upon to maintain competitiveness in the future. Factors such as market access and intellectual property protection would gauge how the UK was viewed relative to the rest of the world — particularly the US.

PICTF focused on six areas of UK competitiveness (market developments, intellectual property rights, regulation of medicines licensing, science base and biopharmaceuticals, clinical research and wider economic climate) considered vital for future performance, and established working groups to examine them. Reliable competitiveness indicators were identified, with the intention of reviewing them annually. A quick look at the DoH site notes that reviews were not published for 2006–2008, though 2009 is available, so perhaps they are back on track (5).

The pharmaceutical industry representatives also used the PICTF initiative as an opportunity to gain commitment from the government to explore some of the industry's concerns. One particular worry at this time was the role that NICE would play in the future UK market (something which continues to trouble the industry today). They sought clarification on the timing of the body's decisions in relation to the availability of data, the limitations of modelling with reference to particular case studies, and how topics were selected for NICE appraisal. Separately, the industry representatives also had helpful discussions with the treasury on a range of fiscal and taxation issues.

PICTF was considered a success in that it established a framework for dialogue on issues over which the government and the pharma industry might differ. However, it also represented high-level recognition from the government that it valued the industry's contribution to the UK economy. The value of PICTF was also recognised by other countries, as well as by the European Commission (EC), and has shaped their own approaches to boosting national and regional R&D. In 2004, for example, the French government launched a similar exercise called PharmaFrance and even sent representatives to the UK to seek company viewpoints on the R&D environment.

Another pharmaceutical R&D initiative that featured UK pharma industry participation was conducted at an overall EU level by the EC's G10 Medicines Group (6). In 2002, the group brought together top European industry and public health decision makers to consider ways of improving competitiveness in line with social and public health objectives. In a similar fashion to PICTF, the G10 group set up a system of EU indicators to allow comparisons to be made between the EU and its major competitors as a basis for establishing best practice within the EU and uptake in each member state. The group also published a report on its findings for the EC, outlining proposals for concrete action to be taken (7).Out of the 14 or so G10 recommendations, perhaps the most one important was to set benchmarks by which Europe could measure its industry productivity against the US. More information was also to be made available regarding disease statistics, as there was an incomplete picture across Europe.

Recognising the growing importance of biotech R&D to the future of new drug development, in 2003, the UK Government launched the Bioscience Innovation and Growth Team (BIGT), which was led by the BioIndustry Association (BIA) in conjunction with the Departments of Trade & Industry and Health. Like PICTF, the BIGT issued a report, following consultation with more than 70 industry experts. Its recommendations included programmes to increase the scientific and managerial talent base available to the biotech sector, with the hope of emulating the leading position of the US in the field of biotech drug development. Many of the recommendations recognised the need for a long-term vision for the industry and reached as far as 2015. Unfortunately, such goals make monitoring its ongoing success difficult.

A much more recent initiative is "Lifescience UK". Launched in January 2011, four key members, the Association of British Healthcare Industries (ABHI), the Association of the British Pharmaceutical Industry (ABPI), the BioIndustry Association (BIA) and the British In Vitro Diagnostics Association (BIVDA), will all represent their own sector interests and work with the government to help strengthen and grow the UK's life sciences environment. Watch this space.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here